


IN THE UNITED STATES PATENT AND TRADEMARK OFFICE



Applicant	:	David A. Brown, Alexander A. Khorlin, Krystyna Lesiak and Wu Yun Ren
Serial No.	:	10/667,630
Filed	:	September 22, 2003
For	:	DERMATOLOGICAL COMPOSITIONS AND METHODS
Examiner	:	N. Nutter
Group	:	1711

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

In accordance with 37 CFR §1.56 and 37 CFR §1.97(c), applicants wish to call the Examiner's attention to References 99-142 listed on the Supplemental Modified 1449 Form submitted herewith. Copies of these references are enclosed.

References 99-101 were cited in a December 23, 2003 communication from the European Patent Office regarding the EP regional phase of PCT Application No. PCT/US97/16642, from which this application claims priority. A copy of the EPO communication, as well as the claims to which it is directed, are attached hereto as Exhibit A. References 99-101 are references D14, D16, and D17 of the communication. The remaining references cited in the communication were previously made of record in this application (see References 2, 4-5, 7, 12, 20, 28, 30-32, 34-35, 38, and 60 of applicants' prior Modified PTO 1449 Form).

Also submitted herewith is a translation of Section 8 of Reference 101 (D17 of the EP prosecution). That section discusses the use of various compounds as choleretics, including two bicyclic monoterpene diols (compounds XIc and XIi of Figure 11).

Commonly-assigned U.S. Patent No. 5,990,177 (Reference 23 of applicants' prior Modified PTO 1449 Form), states that stimulation of the NO/cGMP/PKG pathway is useful for treatment of microvascular irregularities in the liver with consequences for biliary transport and tissue regeneration. The '177 patent cites Suematsu et al., 1996, Cardiovasc. Res., 32:679-686 (Reference 102 of the attached Supplemental Modified PTO 1449 Form), in connection with this disclosure.¹

¹ References 120-142 submitted herewith are the remaining references which are referred to in the '177 patent in connection with its list of diseases that can be treated through the NO/cGMP/PKG pathway (see column 3, line 12, to column 4, line 5, of the '177 patent).

References 103-119 submitted herewith are the results of a literature search performed to determine if the NO/cGMP/PKG pathway is, in fact, involved in the choleric activity of the two bicyclic monoterpene diols discussed in Section 8 of Reference 101.

The literature search found that some studies refer to nitric oxide or cGMP dependent mechanisms for choleresis (Myers et al., 1996 (Reference 115); St-Pierre et al., 1996 (Reference 116); Trauner et al., 1997 (Reference 118); Trauner et al., 1998 (Reference 119); and Taniai et al., 2001 (Reference 117)). However, there are many more studies showing choleresis is mediated by a cAMP dependent pathway (Barnhart and Combes, 1975 (Reference 104); Levine and Hall, 1976 (Reference 113); Larsen et al., 1979 (Reference 109); Anwer et al., 1984 (Reference 103); Kaminski and Deshpande, 1984 (Reference 108); Lenzen et al., 1992 (Reference 110); Lenzen and Tavoloni, 1993 (Reference 111); McGill et al., 1994 (Reference 114); Francis et al., 2004 (Reference 107); LeSage et al., 2004 (Reference 112)).

A paper was also found which showed choleresis induced by bombesin independent of cAMP, cGMP or Ca^{++} (Cho, 1997 (Reference 106)).

In addition, the literature search identified a medicinal compound, i.e., Epomediol (Clesidren)(1,3,3-trimethyl-2-oxabicyclo 2.2.2 octan-6,7-endo, endo-diol), which is approved in Italy for use in increasing bile secretion and is a bicyclic monoterpene diol with an oxygen within the bicyclic ring structure. This drug appears to act by stimulating ATPase, Ca^{++} , and adenylate cyclase (Barrera and Parola, 1984 (Reference 105)). No studies were found connecting Epomediol with nitric oxide or cGMP.

Overall, the majority of the papers find that choleresis is induced via a cAMP dependent pathway, not a cGMP process, which means that nitric oxide is not part of the mechanism. Therefore, applicants believe that it would be incorrect to conclude that a compound that induces choleresis acts via the nitric oxide pathway. In particular, applicants submit that it would be incorrect to conclude that the bicyclic monoterpene diols of Reference 101 act via nitric oxide/cGMP to induce choleresis. In addition to the weight of the academic studies, the work on the medicinal compound Epomediol leads to the conclusion that bicyclic monoterpene diols induce choleresis via an adenylate cyclase/cAMP pathway, not the NO/cGMP/PKG pathway of applicants' claims.

Applicants would also like to bring to the attention of the Examiner the following papers of abandoned U.S. Application No. 09/086,548, which was filed on May 28, 1998 in the

names of David A. Brown and Wu Yun Ren: 1) the application as filed, 2) an August 24, 1998 Response to Election of Species Requirement, 3) a September 12, 1998 Office Action, 4) a January 12, 1999 Amendment, and 5) an April 14, 1999 Final Office Action. A copy of these papers is attached hereto as Exhibit B.

The Examiner is respectfully requested to initial a copy of the Supplemental Modified 1449 Form submitted herewith and return it to applicants to indicate consideration of the references listed thereon in connection with the prosecution of this application.

Pursuant to 37 CFR §1.97(c) and 37 CFR §1.17(p), a check for \$180.00 is enclosed. The Commissioner is hereby authorized to charge any additional fees which may be required by this paper, or credit any overpayment, to Deposit Account No. 11-1158.


Respectfully submitted,

Date: 2/10/05

Maurice M. Klee

Maurice M. Klee, Ph.D.
Reg. No. 30,399
Attorney for Applicant
1951 Burr Street
Fairfield, CT 06824
(203) 255-1400

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE



Applicant : David A. Brown, Alexander A. Khorlin, Krystyna Lesiak
 and Wu Yun Ren
 Serial No. : 10/667,630
 Filed : September 22, 2003
 Title : DERMATOLOGICAL COMPOSITIONS AND
 METHODS

SUPPLEMENTAL MODIFIED 1449 FORMU.S. PATENT DOCUMENTS

<u>Examiner Initial</u>	<u>Document Number</u>	<u>Issue Date</u>	<u>Name</u>
_____	99. 5,190,978	3/1993	Nakamura et al.
_____	100. 5,525,635	6/1996	Moberg

OTHER ART

<u>Examiner Initial</u>	
_____	101. Krieger, H. "Arzneimittelforschung an Norbornan-Derivaten 2. Mitteilung," ARZNEIMITTEL-FORSCHUNG, vol. 18, no. 3 1968, pages 324-330, XP009020785, with attached English translation of Section 8.
_____	102. Suematsu et al., "Gaseous monoxides: a new class of microvascular regulator in the liver," <u>Cardiovascular Research</u> , 32: 679-686, 1996.
_____	103. Anwer et al., "Essential Role of Sodium and Chloride for Theophylline-Induced Choleresis in the Isolated Perfused Rat Liver," <u>Proceedings of the Society for Experimental Biology and Medicine</u> , 176:70-76, 1984.

-
104. Barnhart et al., "Characteristics Common to Choleretic Increments of Bile Induced by Theophylline, Glucagon and SQ-20009 in the dog," Proceedings of the Society for Experimental Biology and Medicine, 150:591-596, 1975.
-
105. Barrera et al., "Effect of Epomediol on the ATPase and Adenylate Cyclase Activities in Plasmamembranes Isolated from Rat Liver," Pharmacological Research Communications, 16:1133-1140, 1984.
-
106. Cho, Won Kyoo, "Role of the Neuropeptide, Bombesin, in Bile Secretion," Yale Journal of Biology and Medicine, 70:409-416, 1997.
-
107. Francis et al., "cAMP stimulates the secretory and proliferative capacity of the rat intrahepatic biliary epithelium through changes in the PKA/Src/MEK/ERK1/2 pathway," Journal of Hepatology, 41:528-537, 2004.
-
108. Kaminski et al., "The Effects of Prostacyclin on Canine Hepatic Bile Flow," Hepatology, 4:644-650, 1984.
-
109. Larsen et al., "The effect of glucagons, dibutyrylic cyclic AMP and theophylline on bile production in the cat," Acta Physiol. Scand., 106:23-27, 1979.
-
110. Lenzen et al., "Secretin stimulates bile ductular secretory activity through the cAMP system," Amer. J. Physiol., 263:G527-532, 1992.
-
111. Lenzen et al., "Glucagon induces biliary protein excretion in guinea pigs," Amer. J. Physiol., 264:G961-G966, 1993.
-
112. LeSage et al., " α -1 Adrenergic Receptor Agonists Modulate Ductal Secretion of BDL Rats via Ca^{2+} - and PKC-Dependent Stimulation of cAMP," Hepatology, 40:1116-1127, 2004.
-
113. Levine et al., "Cyclic AMP in Secretin Choleresis: Evidence for a regulatory role in man and baboons but not in dogs," Gastroenterology, 70:537-544, 1976.

- _____ 114. McGill, et al., "Secretin activates C1-channels in bile duct epithelial cells through a cAMP-dependent mechanism," Amer. J. Physiol., 266:G731-G736, 1994.
- _____ 115. Myers et al., "cGMP stimulates bile acid-independent bile formation and biliary bicarbonate excretion," Amer. J. Physiol., 270:G418-G424, 1996.
- _____ 116. St-Pierre et al., "Stimulation of Bile Acid Independent Bile Flow with Bromo-Cyclic Guanosine Monophosphate," Hepatology, 24:1487-1491, 1996.
- _____ 117. Taniai et al., "Endothelin B Receptor-Mediated Protection Against Anoxia-Reoxygenation Injury in Perfused Rat Liver: Nitric Oxide-Dependent and -Independent Mechanisms," Hepatology, 33:894-901, 2001.
- _____ 118. Trauner et al., "Nitric Oxide Donors Stimulate Bile Flow and Glutathione Disulfide Excretion Independent of Guanosine 3', 5'-Cyclic Monophosphate in the Isolated Perfused Rat Liver," Hepatology, 25:263-269, 1997.
- _____ 119. Trauner et al., "Nitric Oxide and Guanosine 3', 5'-Cyclic Monophosphate Stimulate Bile Secretion in Isolated Rat Hepatocyte Couplets, But Not in Isolated Bile Duct Units," Hepatology, 28:1621-1628, 1998.
- _____ 120. Adnot et al., "Pulmonary hypertension: NO therapy?," Thorax, 1996, 51:762-764.
- _____ 121. Andersson and Stief, "Neurotransmission and the contraction and relaxation of penile erectile tissues," 1997, World J. Urol. 15:14-20.
- _____ 122. Andersson, K.-E., "Neurotransmitters and neuroreceptors in the lower urinary tract," Curr. Opin. Obstet. Gynecol., 1996, 8:361-365.
- _____ 123. Baron, A., "Insulin and the Vasculature--Old Actors, New Roles," J. Investig. Med., 1996, 44:406-412.

- _____ 124. Brann et al., "Gaseous Transmitters and Neuroendocrine Regulation," Neuroendocrinology, 1997, 65:385-395.
- _____ 125. Carter et al., "Nitric oxide production is intensely and persistently increased in tissue by thermal injury," Biochem. J., 1994, 304(Pt 1):201-04.
- _____ 126. Cooke and Dzau, "Nitric Oxide Synthase: Role in the Genesis of Vascular Disease," Annu. Ref. Med., 48:489-509, 1997.
- _____ 127. Dawson et al., "Nitric Oxide Actions in Neurochemistry," Neurochem. Int., 1996, 29:97-110.
- _____ 128. Gorfine, S., "Treatment of Benign Anal Disease with Topical Nitroglycerin," Dis. Colon Rectum, 1995, 38:453-456.
- _____ 129. Kone, et al., "Biosynthesis and homeostatic roles of nitric oxide in the normal kidney," Am. J. Physiol., 1997, 10:F561-578.
- _____ 130. Lahera, et al., "Nitric Oxide, the Kidney, and Hypertension," , Am. J. Hypertens. 10:129-140, 1997.
- _____ 131. Marriott and Higenbottam, "The role of nitric oxide in respiratory disease," 1997, Schweiz Med. Wochenschr. 127:709-714 (abstract).
- _____ 132. Mashimo et al., "Effects of Vasodilators Guanethidine, Nicardipine, Nitroglycerin, and Prostaglandin E₁ on Primary Afferent Nociceptors in Humans," J. Clin. Pharmacol., 1997, 37:330-335.
- _____ 133. Murrell et al., "Modulation of tendon healing by nitric oxide," Inflamm. Res., 1997, 46:19-27.
- _____ 134. Packard et al., "Pathogenesis of Posttraumatic Headache and Migraine: A Common Headache Pathway?" Headache, 1997, March 37:142-152.

- _____ 135. Pipili-Synetos et al., "Inhibition of angiogenesis, tumour growth and metastasis by the NO-releasing vasodilators, isosorbide mononitrate and dinitrate," Br. J. Pharmacol., 1995, 116:1829-1834.
- _____ 136. Rishi et al, " Gastrointestinal Protection by NO from NSAIDs Induced Injury," Indian J. Physiol. Pharmacol., 1996, 40:377-379.
- _____ 137. Rubbo et al, "Nitric Oxide Regulation of Tissue Free Radical Injury," Chem. Res. Toxicol., 1996, 9:809-820.
- _____ 138. Samdani et al, "Nitric Oxide Synthase in Models of Focal Ischemia," Stroke, 1997, 28:1283-1288.
- _____ 139. Schaffer et al., "Nitric Oxide Regulates Wound Healing," J. Surg. Res., 1996, 63:237-240.
- _____ 140. Thadani, U., "Nitrate Tolerance, Rebound, and their Clinical Relevance in Stable Angina Pectoris, Unstable Angina and Heart Failure," Cardiovasc. Drugs, 1997, 10:735-742.
- _____ 141. Tooke et al, "Microvascular functional abnormalities in diabetes: the role of the endothelium," Diabetes Res. Clin. Pract., 1996, 31Suppl:S127-S132.
- _____ 142. Xie et al., "Activation of nitric oxide synthase gene for inhibition of cancer metastasis," J. Leukoc. Biol., 1996, 59:797-803.